The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions

被引:16
|
作者
Atkin, Catherine [1 ]
Reddy-Kolanu, Vinay [2 ]
Drayson, Mark T. [3 ]
Sapey, Elizabeth [1 ]
Richter, Alex G. [3 ]
机构
[1] Univ Birmingham, Inst Inflammat & Ageing, Birmingham Acute Care Res, Birmingham B15 2GW, W Midlands, England
[2] Queen Elizabeth Hosp, Dept Acute Med, Birmingham, W Midlands, England
[3] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
关键词
monoclonal gammopathy of undetermined significance; acute medicine; infection; screening; renal dysfunction; CHAIN DEPOSITION DISEASE; MULTIPLE-MYELOMA; SIGNIFICANCE MGUS; GUIDELINES; MANAGEMENT; RISK; DIAGNOSIS; PROGRESSION; SURVIVAL; THERAPY;
D O I
10.1111/bjh.16487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) affects 3 center dot 2% of adults aged >50 years. MGUS carries a life-long risk of progression to multiple myeloma and causes complications including infection and renal impairment; common causes of hospital admission. This study aimed to assess MGUS prevalence in emergency medical hospital admissions. Patients were recruited from unselected emergency medical admissions in a hospital in the United Kingdom. Serum protein electrophoresis was performed, with immunofixation of abnormal results. Reason for admission and routine test results were recorded. After education about MGUS and myeloma, patients chose whether they wished to be informed of new diagnoses. A total of 660 patients were tested and 35 had a paraprotein suggestive of MGUS. The overall rate of MGUS was 5 center dot 3%. MGUS prevalence in those aged >50 years was 6 center dot 94%, higher than the previously published rate of 3 center dot 2% (P < 0 center dot 0005). There were higher rates in those with chronic kidney disease (13 center dot 75% vs. 4 center dot 14%, P = 0 center dot 002), heart failure (14% vs. 4 center dot 59%, P = 0 center dot 012), anaemia (8 center dot 96% vs. 3 center dot 41%, P = 0 center dot 003) or leucocytosis (9 center dot 33% vs. 3 center dot 04%, P = 0 center dot 002). In all, 96% of patients wished to be informed of their screening results. The prevalence of MGUS in emergency hospital admissions is higher than expected based on previous population-based rates. This may suggest a selected population for screening.
引用
收藏
页码:1127 / 1135
页数:9
相关论文
共 50 条
  • [41] Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance
    Rajkumar, S. Vincent
    CLINICAL CANCER RESEARCH, 2009, 15 (18) : 5606 - 5608
  • [42] Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
    Kaur, Jasneet
    Valisekka, Sai Sudha
    Hameed, Maha
    Bandi, Pushyami Satya
    Varma, Samyukta
    Onwughalu, Chibuzor Joseph
    Ibrahim, Hany
    Mongia, Himani
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05) : E195 - E212
  • [43] The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance
    Batko, Krzysztof
    Malyszko, Jolanta
    Jurczyszyn, Artur
    Vesole, David H.
    Gertz, Morie A.
    Leleu, Xavier
    Suska, Anna
    Krzanowski, Marcin
    Sulowicz, Wladyslaw
    Malyszko, Jacek S.
    Krzanowska, Katarzyna
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (09) : 1440 - 1452
  • [44] On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS)
    Ruiz-Argueelles, Guillermo J.
    Ruiz-Delgado, Guillermo J.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (01) : 144 - 145
  • [45] On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS)
    Guillermo J. Ruiz-Argüelles
    Guillermo J. Ruiz-Delgado
    International Journal of Hematology, 2012, 96 : 144 - 145
  • [46] Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance
    Georgakopoulou, Rebecca
    Andrikopoulou, Angeliki
    Sergentanis, Theodoros N.
    Fiste, Oraianthi
    Zagouri, Flora
    Gavriatopoulou, Maria
    Psaltopoulou, Theodora
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06) : 361 - 367
  • [47] IgD monoclonal gammopathy of undetermined significance
    Kinoshita, T
    Nagai, H
    Murate, T
    Saito, H
    Fukatsu, T
    Hotta, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1997, 65 (02) : 169 - 172
  • [48] Prognosis in monoclonal gammopathy of undetermined significance
    Vuckovic, J
    Ilic, A
    Knezevic, N
    Marinkovic, M
    Zemunik, T
    Dubravcic, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) : 649 - 651
  • [49] Patient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS)
    Murphy, Blain
    McShane, Charlene M.
    Santin, Olinda
    Treanor, Charlene
    Byrne, Bronagh
    Donnelly, Michael
    Anderson, Lesley A.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2021, 51
  • [50] Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites
    Greenberg, A. J.
    Vachon, C. M.
    Rajkumar, S. V.
    LEUKEMIA, 2012, 26 (04) : 609 - 614